FDC Limited has received Abbreviated New Drug Application approval from the United States Food and Drug Administration for Cefixime for Oral Suspension, the company disclosed on May 18, 2026.
Cefixime for Oral Suspension is a third-generation oral cephalosporin antibiotic used in the treatment of a range of bacterial infections including respiratory tract infections, urinary tract infections, ear infections — commonly known as otitis media — and throat infections. The oral suspension formulation is particularly important for the paediatric segment, where the ability to administer an antibiotic as a liquid rather than a tablet is a key clinical requirement. Cefixime is a well-established generic molecule with broad prescribing across both adult and paediatric populations in the United States.
The ANDA approval from the USFDA authorises FDC to commercially market and sell the product in the United States — the world’s largest pharmaceutical market — following demonstration that the generic product is bioequivalent to the reference listed drug. FDC has not disclosed the size of the addressable market for this specific formulation or a launch timeline in the current disclosure.
FDC Limited is a Mumbai-based pharmaceutical company with a significant domestic branded formulations presence and an established international generics business. The company has been building its US ANDA portfolio as part of a strategy to diversify revenue beyond the Indian domestic market and generate dollar-denominated export income — a particularly relevant strategic priority given the current rupee weakness at record lows near 96.
US ANDA approvals, while not immediately translating to large revenue contributions in an established generic market, represent a cumulative building of the US-addressable product portfolio that supports the long-term trajectory of FDC’s international generics business.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making investment decisions.